Litcius/Paper detail

Adjuvant-free peptide vaccine targeting Clec9a on dendritic cells can induce robust antitumor immune response through Syk/IL-21 axis

Shanshan Gou, Shuai Wang, Wenwen Liu, Guanyu Chen, Dongyang Zhang, Jiangfeng Du, Zhongyi Yan, Hongfei Wang, Wenjie Zhai, Xinghua Sui, Yahong Wu, Yuanming Qi, Yanfeng Gao

2021Theranostics40 citationsDOIOpen Access PDF

Abstract

CBP-12 could serve as an adjuvant-free peptide vaccine carrier for cancer immunotherapy.

Topics & Concepts

AdjuvantAntigenCross-presentationImmune systemCytotoxic T cellDendritic cellImmunologyAntigen presentationCD8EpitopeCancer immunotherapyCancer researchCancer vaccineT cellImmunotherapyChemistryBiologyBiochemistryIn vitroImmunotherapy and Immune ResponsesCancer Immunotherapy and BiomarkersRNA Interference and Gene Delivery
Adjuvant-free peptide vaccine targeting Clec9a on dendritic cells can induce robust antitumor immune response through Syk/IL-21 axis | Litcius